Search research articles
Contact Us
Filters
Showing results (51-60 of 90) with videos related to
Page
of 9
Sort By:
Epidemiology and Infection
|
September 14, 2013
Respiratory morbidity of preterm infants of less than 33 weeks gestation without bronchopulmonary dysplasia: a 12-month follow-up of the CASTOR study cohort
B Fauroux, J-B Gouyon, J-C Roze, et al.
ESMO Open
|
April 5, 2021
COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?
N Silvestris, M Di Maio, A Russo, et al.
British Journal of Cancer
|
May 9, 2007
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group
S Pignata, G Scambia, C Pisano, et al.
Breast (Edinburgh, Scotland)
|
March 25, 2025
Integration of translational research in phase III trials: A systematic review of breast cancer studies in a 5-year period
G Giannone, P Lombardi, M Filetti, et al.
Drugs of Today (Barcelona, Spain : 1998)
|
October 23, 2010
Vandetanib: An overview of its clinical development in NSCLC and other tumors
A Morabito, M C Piccirillo, R Costanzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2011
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study
C Gridelli, F Morgillo, A Favaretto, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Adoption of electronic patient-reported outcomes in cancer clinical practice: the point of view of Italian patients
A A Valsecchi, V Battista, S Terzolo, et al.
British Journal of Cancer
|
April 20, 2006
Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial
C Pacilio, A Morabito, F Nuzzo, et al.
ESMO Open
|
June 4, 2023
Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology
A G Leone, R Miceli, D Trapani, et al.
Cancer Research and Treatment
|
November 19, 2016
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis
Chiara Cremolini, Carlotta Antoniotti, Filippo Pietrantonio, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 90) with videos related to
Sort By:
Page
of 9
Epidemiology and Infection
|
September 14, 2013
Respiratory morbidity of preterm infants of less than 33 weeks gestation without bronchopulmonary dysplasia: a 12-month follow-up of the CASTOR study cohort
B Fauroux, J-B Gouyon, J-C Roze, et al.
ESMO Open
|
April 5, 2021
COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?
N Silvestris, M Di Maio, A Russo, et al.
British Journal of Cancer
|
May 9, 2007
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group
S Pignata, G Scambia, C Pisano, et al.
Breast (Edinburgh, Scotland)
|
March 25, 2025
Integration of translational research in phase III trials: A systematic review of breast cancer studies in a 5-year period
G Giannone, P Lombardi, M Filetti, et al.
Drugs of Today (Barcelona, Spain : 1998)
|
October 23, 2010
Vandetanib: An overview of its clinical development in NSCLC and other tumors
A Morabito, M C Piccirillo, R Costanzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2011
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study
C Gridelli, F Morgillo, A Favaretto, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Adoption of electronic patient-reported outcomes in cancer clinical practice: the point of view of Italian patients
A A Valsecchi, V Battista, S Terzolo, et al.
British Journal of Cancer
|
April 20, 2006
Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial
C Pacilio, A Morabito, F Nuzzo, et al.
ESMO Open
|
June 4, 2023
Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology
A G Leone, R Miceli, D Trapani, et al.
Cancer Research and Treatment
|
November 19, 2016
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis
Chiara Cremolini, Carlotta Antoniotti, Filippo Pietrantonio, et al.
Page
of 9